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Comparison of the Bronchodilative
Effects of Salbutamol Delivered via
Three Mesh Nebulizers in Children
with Bronchial Asthma
Fumitake Kurosaka1 and Hisahide Nishio2
ABSTRACT
Background: We compared the bronchodilative effects of salbutamol delivered via 3 different mesh nebuliz-
ers, Aeroneb-goⓇ(AE), Omron-NE-U22Ⓡ(OM) and Pari-eMotionⓇ(PA).
Methods: We enrolled 36 children with asthma who visited the Kurosaka Pediatrics and Allergy Clinic, ran-
domly assigned to 3 groups for treatment with AE, OM or PA. The dose of salbutamol in the solution was 0.15
mg × body weight (kg) (minimum 2.5 mg, maximum 5 mg). FEV1, PEFR and V50 were measured in these pa-
tients before treatment, and at 15 and 30 minutes after salbutamol inhalation using one of the 3 mesh nebuliz-
ers.
Results: All groups showed a significant improvement of FEV1, PEFR and V50 at 30 minutes after salbutamol
inhalation. The AE group did not show a significant improvement in PEFR at 15 minutes after inhalation,
whereas a significant improvement in FEV1 and V50 was evident at the same time point. The OM group showed
no significant improvement in V50 at 15 minutes after inhalation, whereas this group clearly showed a significant
improvement in PEFR and FEV1 at the same time point.
Conclusions: Overall, all 3 mesh nebulizers were useful devices in treating bronchial asthma, although some
differences in lung function improvement were evident. The limitation of this study is that subjects did not in-
clude patients with severe asthma attacks.
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INTRODUCTION
Inhalation therapy with nebulizers which can deliver
drugs to the lungs directly and increase their thera-
peutic effects began in the 1950s.1 Inhalation therapy
with nebulizers is advantageous because the risk of
adverse effects is lower than systemic drug admini-
stration, such as oral administration.2 Inhalation ther-
apy with steroids and bronchodilators has been in-
creasing in importance, and now represents the main-
stream of treatment for bronchial asthma in all age
groups,3 both for long-term control and relief of acute
exacerbation.4
Jet nebulizers now occupy an important position in
inhalation therapy, although the Global Initiative for
Asthma (GINA) recommend a metered-dose inhaler
(MDI) with a spacer as the first choice for children
with bronchial asthma, and nebulizer therapy as the
second choice.4 However, it is well known that jet
nebulizers are noisy and have a large residual
nebulizer-solution volume (or dead volume) within
the reservoir that cannot be nebulized.5,6
Recent developments in mesh nebulizers have im-
proved their practical use. Compared with jet nebuliz-
ers, mesh nebulizers have several distinct merits: (1)
consistent and high aerosol generation efficiency, (2)
predominant delivery of a fine-particle aerosol capa-
ble of reaching the peripheral airways, (3) a low re-
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Fig. 1 The 3 mesh nebulizers.
sidual nebulizer-solution volume, and (4) the ability
to nebulize even microliter volumes.1
However, the kinds of mesh nebulizers that are
best suited for inhalation treatment of bronchial
asthma are yet to be clarified. In this study, we com-
pared the bronchodilator effects of salbutamol deliv-
ered via 3 different mesh nebulizers used in Japan.
METHODS
PATIENTS AND NEBULIZERS
A total of 36 children with asthma aged between 8
and 13 years with less than 70% of predicted forced
expiratory volume in 1 second (FEV1), who had not
used any bronchodilators during the previous 12
hours, were studied. They visited the Kurosaka Pedi-
atrics and Allergy Clinic because of their asthmatic at-
tack. Patients with lung functions which could not be
measured due to acute severe asthma were excluded.
Predicted FEV1 was expressed according to the for-
mula reported by Nishima.7 Written informed con-
sent was obtained from all patients andor their par-
ents.
Three mesh nebulizers used in this study were as
follows: Aeroneb-goⓇ(AE) (Aerogen Ltd., Galway,
Ireland), Omron-NE-U22Ⓡ(OM) (Omron, Kyoto, Ja-
pan) and Pari-eMotionⓇ(PA) (PARI Gmbh, Starn-
berg, Germany) (Fig. 1).
Patients were randomly assigned to 3 groups, ac-
cording to treatment with either of AE, OM or PA. As
shown in Table 1, there were no significant differ-
ences in age and FEV1, peak expiratory flow rate
(PEFR) and maximum expiratory flow rate at 50% of
forced vital capacity (V50) before treatment among
the groups.
SALBUTAMOL DOSES
Salbutamol dose was determined as 0.03 ml (0.15
mg) × body weight (kg) (min. 0.5 ml [2.5 mg],
max.1.0 ml [5 mg]) in accordance with the Expert
Panel Report 3.8 The mean salbutamol dose was 0.8
ml for the AE and OM groups, and 0.9 ml for the PA
group. Nebulized salbutamol was administered via a
mouthpiece.
Physiological saline was added so that the inhala-
tion time was 5 minutes and total inhalation volumes
for the AE, OM and PA were 2.3, 2.3 and 4.3 ml, re-
spectively, following the recommendations of the
British Thoracic Society Nebuliser Project Group.9
LUNG FUNCTION
Lung function parameters were measured with a spi-
rometer, Auto Spiro AS-303 (Minato Medical Science,
Osaka, Japan) which was calibrated each day using a
2-liter syringe (Minato Medical Science, Osaka, Ja-
pan). Subjects performed forced expiratory maneu-
vers and were verbally encouraged to continue to ex-
hale at the end of expiration to obtain optimal effort.
At least 3 maneuvers were required to obtain the
most acceptable flow volume curve.10 FEV1, PEFR
and V50 were measured based on the best curve be-
fore salbutamol inhalation and at 15 and 30 minutes
after inhalation.
RESIDUAL NEBULIZER-SOLUTION VOLUME
Residual nebulizer-solution volume in the aerosoliza-
tion head of the nebulizers was measured using an
electronic balance (Shimadzu, Kyoto, Japan). The
weight of the nebulizer head were compared before
and after inhalation.
STATISTICAL ANALYSIS
Data were expressed as means and standard devia-
tions. One-way ANOVA and Kruskal-Wallis test were
used for comparisons between groups. Dunnett’s test
was applied for comparisons before and after inhala-
tion. For repeated measures ANOVA was used to
analyze groups and changes in lung function at 0, 15
and 30 minutes. Probability (p) values of less than
0.05 were considered to indicate statistically signifi-
cant differences. Statistical analysis was performed
with SPSS version 13 (SPSS, Tokyo, Japan).
RESULTS
LUNG FUNCTION CHANGES
All three groups, AE, OM and PA, showed significant
improvement in FEV1 at 15 and 30 minutes after sal-
butamol inhalation (Fig. 2, Table 2) in comparison
with the baseline values. Although the order of the
average rank of the degree of lung function change
for the 3 mesh nebulizers were estimated (PA>OM>
AE for FEV1 at 15 minutes, and PA>AE>OM for FEV
1 at 30 minutes), they did not show any significant
changes on the Kruskal-Wallis test (Table 3).
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Table 1 Demography of patient population
P-valuePari-eMotionOmron-U-22Aeroneb-go®Patient
121212n
ns† 8/4 8/3 7/5Boy/girl
ns†(1.4)9.9(1.9)9.9(1.3)9.0Age (y)
ns†(9.2)134.5(16.8)137.0(10.1)131.7Height (cm)
ns†(6.7)30.8(18.3)34.5(6.9)28.4Body weight (kg)
ns†(11.6)51.0(8.8)56.8(9.2)56.9%FEV1
ns†(0.32)0.97(0.49)1.12(0.28)1.00FEV1 (L)
ns†(0.68)2.15(0.99)2.38(0.64)2.21PEFR (L/s)
ns†(0.32)0.97(0.28)1.12(0.28)1.00V50 (L/s)
ns†(20)106(16)97(15)101Heart rate (bpm)
ns†(0.14)0.88(0.13)0.83(0.16)0.81Dose (mL) ‡ ,§
† Kruskal-Walis test.
‡ One-way ANOVA.
§ Salbutamol dose.
Data are expressed as mean (standard deviation). ns, not significant.
Regarding PEFR, the OM and PA groups, showed
significant improvement at 15 minutes after salbuta-
mol inhalation compared with the baseline. However,
the AE group did not show any significant improve-
ment at the same time point. All 3 mesh nebulizers
achieved a significant improvement in PEFR at 30
minutes after salbutamol inhalation compared with
the baseline (Fig. 2, Table 2). Although the order of
the average rank of the degree of lung function
change for the 3 mesh nebulizers were estimated
(OM>PA>AE for PEFR at 15 and 30 minutes), they
did not indicate any significant differences on the
Kruskal-Wallis test (Table 3).
With regard to V50, the 2 groups, AE and PA,
showed significant improvement at 15 minutes after
salbutamol inhalation compared with the baseline.
The OM group, however, did not show any signifi-
cant improvement at the same time point but all 3
mesh nebulizers achieved a significant improvement
in V50 at 30 minutes after salbutamol inhalation com-
pared with the baseline (Fig. 2, Table 2). Although
the order of the average rank of the degree of lung
function change for the 3 mesh nebulizers were esti-
mated (PA>AE>OM for V50 at 15 minutes, and PA>
OM>AE for V50 at 30 minutes), they showed no sig-
nificant differences on the Kruskal-Wallis test (Table
3).
HEART RATES
None of the patients complained of adverse reactions.
However, the patients’ heart rates significantly in-
creased at 30 minutes after salbutamol inhalation
(Fig. 3). The increase in heart rate may have been
due to the beta 2-agonist effect of salbutamol, al-
though this has not been used as an indicator of bron-
chodilative effects.11 There was no significant differ-
ence in the patients’ heart rates among cases using
the 3 mesh nebulizers at 15 and 30 minutes after sal-
butamol inhalation.
RESIDUAL NEBULIZER-SOLUTION VOLUME
Mean residual nebulizer-solution volumes in the AE,
OM and PA groups were 1.11 ± 0.17 (mean ± SD, n =
5), 0.17 ± 0.07 and 0.73 ± 0.08 grams, respectively. Re-
sidual nebulizer-solution volume in the OM was sig-
nificantly less than in the other 2 nebulizers on the
Kruskal-Wallis test, and that of the AE was the largest
among the three (Fig. 4).
DISCUSSION
AEROSOL MASS MEDIAN AERODYNAMIC DI-
AMETER (MMAD)
This is the first reported study to have compared the
bronchodilative effects of salbutamol delivered via 3
mesh nebulizers; the AE, OM and PA, in children
with bronchial asthma. We demonstrated that all 3
nebulizers improved lung function in children with
moderate exacerbations at 30 minutes after salbuta-
mol inhalation.
Whether inhalation using a nebulizer brings about
successful improvement in lung function depends
mainly on the respirable particles.8 Aerosol particles
larger than 5 to 7 μm tend to halt in the upper airway,
either at the internal ostium (located at the entrance
to the nasal cavity) when inhaled through the nose,
or in the oral cavity, oropharynx and larynx when in-
haled through the mouth.12-15 In general, the MMAD
should be less than 5 μm to deliver aerosol particles
generated by a nebulizer into the lung. Here, we dis-
cuss the bronchodilative effects of salbutamol deliv-
ered via 3 mesh nebulizers, from the viewpoint of
MMAD.
Aeroneb-goⓇ(AE)
The AE utilizes “Aeroneb Pro” technology. Ease of
assembly, silent operation and simplified cleaning im-
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Fig. 2 Changes in lung function folowing salbutamol inha-
lation in patients with asthma exacerbation. AE, Aeroneb-
go®; OM, Omron-NE-U22®; PA, Pari-eMotion®. *P < 0.05, 
**P < 0.005. Each point represents the mean and S.D.
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proves the treatment regimen for patients and
caregivers and can facilitate discrete therapy within a
shorter duration for each treatment compared with
conventional jet nebulizers.1 The MMAD of aerosol
particles with a budesonide suspension delivered by
the AE is 3.1 ± 1.6 μm.16
In our study, the AE group did not show a signifi-
cant improvement in PEFR at 15 minutes after salbu-
tamol inhalation, while there was a significant im-
provement in FEV1 and V at the same time point 50.
Since PEFR represents large airway function,17 the
failure to improve PEFR implies that the aerosol parti-
cles generated by the AE were so small that they
passed through the large airway. Another possible
explanation is that the amount of salbutamol deliv-
ered via the AE was insufficient to improve PEFR at
15 minutes, because the AE had the largest residual
nebulizer-solution volume among the 3 nebulizers,
suggesting that a proportion of the solution cannot be
nebulized effectively.
Omron-NE-U22Ⓡ(OM)
The vibrating mesh of the OM consists of a metal al-
loy with approximately 6,000 holes.1 Pulmonary
bioavailability assessments of salbutamol nebulized
by the OM using 99mTc gamma-scintigraphy have
demonstrated a lung drug deposition approximately
2.8 times higher than that achieved with a jet nebu-
lizer.1 The MMAD of aerosol particles generated by
the OM at room temperature or 4℃ for NaF and sal-
butamol is 4.3-4.5 μm.18
In the present study, the OM group did not show a
significant improvement in V50 at 15 minutes after sal-
butamol inhalation, whereas significant improve-
ments in PEFR and FEV1 were evident at the same
time point. The average residual volume of the OM
was only 0.17 g, suggesting that sufficient volume can
be inhaled with this nebulizer. Since V50 represents
small airway function,18 in children19 as well as
adults, the failure to improve V50 implies that the
aerosol particles generated by the OM are large
enough to be trapped in the large airway and cannot
facilitate significant improvement in small airway
function.
Pari-eMotionⓇ(PA)
The PA is a small, silent and portable device. If the
drug solution disappears, a sensor terminates deliv-
ery automatically. According to the manufacturer’s
specifications, MMADs of aerosolized particles of
budesonide, salbutamol and disodium cromoglycate
are 4.5, 4.3 and 4.3 μm, respectively. The PA, which is
available only in Japan, is similar to the mesh nebu-
lizer eFlowⓇ, used widely in European countries.
In our study, PA showed the greatest improvement
in the degree of change in FEV1 (15 and 30 minutes)
and V50 (15 and 30 minutes) among the 3 mesh nebu-
lizers. Significant differences in FEV1, PEFR and V50
for the PA after 15 minutes may indicate that both
particle size and the amount of actually inhaled salbu-
tamol are sufficiently effective.
SALBUTAMOL DOSES AND ABSORPTION IN
THE BODY
Salbutamol dose (0.15 mgkg) is widely accepted for
nebulization in the USA8 and the UK.9 The dose was
decided based on those described in Expert Panel
Report 3 2007,8 which were higher than those recom-
mended in the Japan guidelines for child asthma.19 In
Comparison of Three Mesh Nebulizers
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Table 2 Comparison of lung function parameters before and after inhalation for each of the nebulizers by Dunnet’s test
Pari-eMotion®Omron-NE-U22®Aeroneb-go®
Time
95% CIP value95% CIP value95% CIP value
0.4280.1530.0000.4290.0930.0030.3010.0540.00515minFEV1
0.4740.1990.0000.4690.1340.0010.3430.0960.00130min
0.8370.1950.0021.1510.2290.0040.656-0.0300.07615minPEFR
0.8890.2470.0011.2420.3210.0010.7820.0960.01230min
0.5730.0990.0050.767-0.0720.1120.6410.1170.00515minV50
0.6430.1690.0010.8720.0330.0340.6620.1380.00330min
Table 3 Comparison of lung function among three kinds of mesh nebulizers using Kruskal-Walis one-way analysis of vari-
ance of rank
 Rank order
Average rank
PVariance
Pari-eMotion®Omron-NE-U22®Aeroneb-go®
 PA>OM>AE†22.0017.0016.5 0.368Change rate of FEV1　(15-0 min)
PA>AE>OM21.8316.7516.920.406(30-0 min)
OM>PA>AE18.3320.0817.080.782PEFR (15-0 min)
OM>PA>AE17.5021.5816.420.448(30-0 min)
PA>AE>OM19.5817.0818.830.837V50 (15-0 min)
PA>OM>AE20.0819.5015.920.577V50 (30-0 min)
† AE, Aeroneb-go®; OM, Omron-NE-U22®; PA, Pari-eMotion®.
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Fig. 3 Changes in heart rate by salbutamol inhalation in 
patients with asthma exacerbation. AE, Aeroneb-go®; OM, 
Omron-NE-U22®; PA, Pari-eMotion®. *P < 0.05, **P < 0.005. 
Each point represents the mean and S.D.
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Fig. 4 Diferences in residual nebulizer-solution volume af-
ter inhalation of OM among the 3 nebulizers by Kruskal-Wal-
lis test (P = 0.002). AE, Aeroneb-go®; OM, Omron-NE-U22®, 
PA, Pari-eMotion®. Each bar represents the mean and S.D.
Japan, however, there have been no reported studies
on the amounts of salbutamol administered via nebu-
lizer inhalation. As patients with exacerbated asthma
require immediate and full-dose treatments, there has
been a need for discussion in Japan about the dose of
salbutamol for this group of patients. The Expert
Panel Report 3 (2007) described that salbutamol is an
effective agonist and has few negative cardiovascular
effects.8 In the present study, no patients complained
of palpitation or tremor.
The results at 15 minutes after inhalation might re-
flect the performance of nebulizers, although the re-
sults at 30 minutes are more useful for the manage-
ment of asthma attacks. In the present study, all 3 of
the AE, OM and PA groups showed a significant im-
provement of FEV1, PEFR and V50 at 30 minutes after
salbutamol inhalation. This can be explained partly by
absorption of salbutamol through the gastro-intestinal
system within 30 minutes after sabutamol inhala-
tion.12-14
RESIDUAL NEBULIZER-SOLUTION VOLUME
The average residual volume for the AE was 1.11 g,
Kurosaka F et al.
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Fig. 5 Main residual volume site of AE. AE, Aeroneb-go®.
i.e., 48.3% of total volume. British nebulizer guide-
lines have suggested that nebulizers with residual
volumes of more than 1.0 ml generally require full
volumes of approximately 4 ml.9 More viscous fluids
require a longer nebulization time and are associated
with increased residual amounts. Ultrasonic nebuliz-
ers are less effective for these more viscous fluids,
and occasionally are unable to nebulize them.20 The
main residual volume of mesh nebulizers lies outside
the mesh membrane and solution reservoir (Fig. 5),
and thus does not affect viscosity. However, the pos-
sibility remains that an excessively large proportion
of residual volume to total volume for the AE will in-
fluence the effectiveness of inhalation. Although the
residual nebulizer-solution volume was significantly
smaller in the OM than in the other 2 nebulizers, the
OM did not yield the greatest improvement in FEV1
and V50. This may suggest that the aerosol from the
OM cannot reach small airways effectively. A limita-
tion of our study may be that our subjects did not in-
clude the patients with severe asthma. There is a pos-
sibility that different results might be gained in the
cases of severe asthma patients whose lung functions
cannot be measured.
CONCLUSIONS
In conclusion, the 3 mesh nebulizers we tested were
shown to be clinically useful for the treatment of pa-
tients with bronchial asthma whose lung function
could be measured, although there were some differ-
ences in the improvement of lung function among
them. In our study, PA showed the greatest improve-
ment in the degree of change of FEV1 (15 and 30 min-
utes) and V50 (15 and 30 minutes) among the 3 mesh
nebulizers. The failure of the AE to improve PEFR at
15 minutes after inhalation may be related to the
small size of the aerosol particles or the large amount
of residual nebulizer solution in the device. The fail-
ure of the OM to improve V50 at 15 minutes after in-
halation may be related to the large size of the aero-
sol particles.
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